Planning Capital Management Corp Buys 30 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Planning Capital Management Corp lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 18.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 190 shares of the medical equipment provider’s stock after acquiring an additional 30 shares during the quarter. Planning Capital Management Corp’s holdings in Intuitive Surgical were worth $93,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Kingsview Wealth Management LLC boosted its stake in Intuitive Surgical by 1.2% in the 1st quarter. Kingsview Wealth Management LLC now owns 4,144 shares of the medical equipment provider’s stock worth $1,654,000 after purchasing an additional 51 shares during the period. Brighton Jones LLC boosted its stake in Intuitive Surgical by 5.2% in the 1st quarter. Brighton Jones LLC now owns 9,314 shares of the medical equipment provider’s stock worth $3,717,000 after purchasing an additional 457 shares during the period. Delos Wealth Advisors LLC boosted its stake in Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 57 shares during the period. Wintrust Investments LLC boosted its stake in Intuitive Surgical by 4.4% in the 1st quarter. Wintrust Investments LLC now owns 40,292 shares of the medical equipment provider’s stock worth $16,080,000 after purchasing an additional 1,696 shares during the period. Finally, M&G Plc bought a new position in Intuitive Surgical in the 1st quarter worth approximately $1,318,000. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Stock Down 0.1 %

Shares of ISRG opened at $536.69 on Thursday. Intuitive Surgical, Inc. has a 52-week low of $287.98 and a 52-week high of $542.59. The company has a market cap of $191.16 billion, a PE ratio of 86.28, a P/E/G ratio of 5.28 and a beta of 1.39. The business has a fifty day moving average of $496.95 and a 200 day moving average of $455.65.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The business had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Evercore ISI restated a “cautious” rating on shares of Intuitive Surgical in a research note on Friday, October 18th. Redburn Atlantic upgraded Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price target for the stock from $380.00 to $510.00 in a research note on Friday, August 2nd. The Goldman Sachs Group set a $604.00 target price on shares of Intuitive Surgical in a report on Friday, October 18th. Raymond James raised their target price on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Finally, Wells Fargo & Company raised their target price on shares of Intuitive Surgical from $466.00 to $549.00 and gave the company an “overweight” rating in a report on Friday, October 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

Insider Transactions at Intuitive Surgical

In other news, insider Jamie Samath sold 22,903 shares of Intuitive Surgical stock in a transaction on Friday, November 8th. The stock was sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the completion of the sale, the insider now directly owns 8,757 shares in the company, valued at approximately $4,597,425. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Jamie Samath sold 22,903 shares of Intuitive Surgical stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $525.00, for a total value of $12,024,075.00. Following the completion of the sale, the insider now directly owns 8,757 shares in the company, valued at $4,597,425. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Robert Desantis sold 188 shares of Intuitive Surgical stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $482.21, for a total value of $90,655.48. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,655,048.26. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 91,178 shares of company stock worth $45,897,071. 0.90% of the stock is currently owned by insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.